title: [Research advances in necessity of antiviral therapy for chronic hepatitis B virus carriers].
abstract: Chronic hepatitis B virus (HBV) carriers are facing the risk of progression to liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. However, due to low risk, slow disease progression, and unsatisfactory short-term effect of antiviral treatment, controversy still exists over whether such patients should be given antiviral treatment. This article reviews the research advances in the necessity and feasibility of antiviral therapy for chronic hepatitis B virus carriers, so as to provide a reference for clinical practice.
authors.affiliation: Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Long
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Yao
authors.forename: C G
authors.initials: CG
authors.lastname: Yan
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control; D002353:Carrier State / Q000188:drug therapy*; D018450:Disease Progression; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000517:prevention & control; D008113:Liver Neoplasms / Q000517:prevention & control
chemical_list: D000998:Antiviral Agents